CFN Media Releases Exclusive Video Series: Dr. Sue Sisley Unlocks Medical Marijuana Efficacy thru Science & Cultivation

Originally posted by Ryan Allaway on April 6, 2017, here

Renowned medical marijuana research scientist Dr. Sue Sisley has pioneered research on the efficacy of medical cannabis as an effective treatment option for veterans suffering from chronic post-traumatic stress disorder (PTSD). In 2014, she secured a rare approval from the federal government to study the effects of marijuana on PTSD.

In 2015, Heliospectra AB (OTCQB: HLSPY) (FIRSTNORTH: HELIO), a world leader in intelligent lighting technology for greenhouse cultivation and plant research, hired Dr. Sue Sisley as its Director of Medical Plant Research. Dr. Sisley and Heliospectra are working with cannabis growers to develop scalable medicinal cultivation methodologies while overseeing data collection and reporting with the company’s medicinal cannabis growers in the U.S., Canada, and around the world.

Heliospectra has enabled Dr. Sisley to continue this groundbreaking research where she plans to publish all results – good or bad – to foster a better understanding of the plant and the transformative effect it can have on patients.

In this video series produced by CFN Media, Dr. Sisley outlines her research ambitions and the potential impact the studies could have on patients while highlighting why Heliospectra’s lighting solutions represent a key breakthrough in the cultivation of medical cannabis.

A Bright Future:

The Science of Medicine and Plants:

Kindred Spirits – Delivering Consistent, Quality Product:

Standardized Medicine – Predictable Results:

Heliospectra AB  (OTCQB: HLSPY) (FIRSTNORTH: HELIO) was founded in 2006 and is the industry’s most proven intelligent lighting technology for greenhouse and controlled plant growth environments, with the vision to make commercial crop production more connected and resource-efficient. Growers and commercial producers across six continents use Heliospectra’s holistic and flexible solutions to consistently increase yields while producing crops that achieve quality appearance, superior nutritional or medicinal value and longer shelf life, harvest after harvest. Winner of multiple international awards and recognitions, Heliospectra has raised more than $32 million in capital to date.

For more information, visit the company’s website or CannabisFN’s company profile.

Leave a Reply

Your email address will not be published. Required fields are marked *